Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.pvr.2017.09.001
Title: Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007–2016
Authors: Gallagher, KE
Howard, N 
Kabakama, S
Mounier-Jack, S
Burchett, HED
LaMontagne, DS
Watson-Jones, D
Keywords: HPV
Vaccine/vaccination
Coverage
Uptake
Completion
Low and middle income countries
Issue Date: 1-Dec-2017
Publisher: Elsevier BV
Citation: Gallagher, KE, Howard, N, Kabakama, S, Mounier-Jack, S, Burchett, HED, LaMontagne, DS, Watson-Jones, D (2017-12-01). Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007–2016. Papillomavirus Research 4 : 72-78. ScholarBank@NUS Repository. https://doi.org/10.1016/j.pvr.2017.09.001
Abstract: Introduction Since 2007, HPV vaccine has been available to low and middle income countries (LAMIC) for small-scale ‘demonstration projects’ or national programmes. We analysed coverage achieved in HPV vaccine demonstration projects and national programmes that had completed at least 6 months of implementation between January 2007–2016. Methods A mapping exercise identified 45 LAMICs with HPV vaccine delivery experience. Estimates of coverage and factors influencing coverage were obtained from 56 key informant interviews, a systematic published literature search of 5 databases that identified 61 relevant full texts and 188 solicited unpublished documents, including coverage surveys. Coverage achievements were analysed descriptively against country or project/programme characteristics. Heterogeneity in data, funder requirements, and project/programme design precluded multivariate analysis. Results Estimates of uptake, schedule completion rates and/or final dose coverage were available from 41 of 45 LAMICs included in the study. Only 17 estimates from 13 countries were from coverage surveys, most were administrative data. Final dose coverage estimates were all over 50% with most between 70% and 90%, and showed no trend over time. The majority of delivery strategies included schools as a vaccination venue. In countries with school enrolment rates below 90%, inclusion of strategies to reach out-of-school girls contributed to obtaining high coverage compared to school-only strategies. There was no correlation between final dose coverage and estimated recurrent financial costs of delivery from cost analyses. Coverage achieved during joint delivery of HPV vaccine combined with another intervention was variable with little/no evaluation of the correlates of success. Conclusions This is the most comprehensive descriptive analysis of HPV vaccine coverage in LAMICs to date. It is possible to deliver HPV vaccine with excellent coverage in LAMICs. Further good quality data are needed from health facility based delivery strategies and national programmes to aid policymakers to effectively and sustainably scale-up HPV vaccination.
Source Title: Papillomavirus Research
URI: https://scholarbank.nus.edu.sg/handle/10635/205255
ISSN: 24058521
DOI: 10.1016/j.pvr.2017.09.001
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.pdfPublished version275.88 kBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.